New ideas to deal with the new situation
Release time:
2020-08-14
Discuss New Ideas in Response to New Situation
Sales Company Discuss Next Stage of Work
News 5# December 3 , Pharmaceutical Sales Company Held a First Quarter Work Conference to Summarize the Work in the First Quarter of Sales, Analyze Existing Problems, and Discuss New Sales Models and New Ideas for Sales Control.
Xu Junxiong, executive deputy general manager of Pharmaceutical Sales Company, summarized the situation of the sales company in the first quarter from the aspects of main work development, agency and terminal sales data, existing problems, etc. Focusing on the work focus of "high goal, increasing measures, emphasizing implementation and having effect", from the aspects of clear rewards and punishment, win-win thinking, emphasizing execution, learning team construction, etc, for the next stage of work, the focus is on the work in the second quarter. Zhou Wenyi, general manager of the pharmaceutical sales company, analyzed the situation of the pharmaceutical industry in the first quarter according to the topics such as the two sessions, the medical insurance catalogue, the consistency evaluation of generic drugs, the two-vote system, and the hot spots in the pharmaceutical industry, and put forward corresponding solutions to the problems of fleeing goods, agreed rebate prices, product problems, academic brands, daily management, etc. At the same time, he also introduced the work direction of the sales company in the next stage from the aspects of channel, promotion, product, price and operation. During the
meeting, Zhang Weidong, quality director of the pharmaceutical company, introduced the object of generic drug consistency evaluation, the implementation stage and the progress of various varieties of the pharmaceutical company. All office managers and regional managers also learned the product knowledge of paroxetine hydrochloride tablets and the operation of the financial reimbursement system, and discussed the 4 topics of how to transform the agency sales, how to carry out the sales after product negotiation, new ideas for controlling sales, and the need for the company's support. According to the actual situation and characteristics of their respective regions, they put forward their own views and suggestions from the aspects of strengthening academic promotion, improving incentive policies, fine investment promotion, risk control, development of remote areas, logistics delivery, and signing of new agreements. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, attended the meeting and commented on the work of the sales company in the first quarter. He asked the sales company to build a good team, purify the existing team with the system, strengthen the training of salesmen, improve their ability, introduce a large number of new people, and set up a good sales control team as soon as possible. Open up a good market, clear the target market, highlight the key points; Sales logistics personnel should go all out to serve the front line and finally realize the leap of sales company's performance. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page